Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gains from Investment Securities (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Gains from Investment Securities for 10 consecutive years, with $681000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 78.43% to $681000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $397000.0, a N/A change, with the full-year FY2025 number at $397000.0, changed N/A from a year prior.
  • Gains from Investment Securities was $681000.0 for Q4 2025 at Rhythm Pharmaceuticals, down from $5.2 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $6.7 million in Q1 2022 to a low of -$5.4 million in Q2 2025.
  • A 5-year average of $446683.5 and a median of $99000.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 166100.0% in 2023, then crashed 1307.07% in 2024.
  • Rhythm Pharmaceuticals' Gains from Investment Securities stood at $1.3 million in 2021, then plummeted by 100.08% to -$1000.0 in 2022, then surged by 166100.0% to $1.7 million in 2023, then soared by 90.18% to $3.2 million in 2024, then plummeted by 78.43% to $681000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Gains from Investment Securities are $681000.0 (Q4 2025), $5.2 million (Q3 2025), and -$5.4 million (Q2 2025).